Celularity Inc.

NASDAQ
CELU
paper.types.company
Rentabilité sur six mois: +15.92%
Rendement en dividendes: 0%
Secteur: Healthcare

2.33 $

-0.05 $ -2.1%
1.08 $
3.83 $

paper.min_max_per_year

Calendrier des promotions Celularity Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Celularity Inc.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.

plus de détails
The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products. The company was founded in 1998 and is based in Florham Park, New Jersey.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2019-08-08
ISIN
US1511901050
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 0.8398 9
P/BV 5.15 3
P/E 0 10
Efficacité
Nom Signification Grade
ROA -41.86 0
ROE -232.51 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.7569 10
Debt/Ratio 0.2188 10
Debt/Equity 14.01 0
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 279.16 10
Rentabilité Ebitda, % -1298.69 0
Rentabilité EPS, % 55.57 7
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 2.38 $ 0 $ 0 $ -2.1 % 0 % 0 %
common.calendar.number_days.7d 2.1 $ 0 $ 0 $ 10.95 % 0 % 0 %
common.calendar.number_days.30d 1.56 $ 1.99 $ 2.49 $ 48.98 % 0 % 0 %
common.calendar.number_days.90d 1.37 $ 1.38 $ 2.49 $ 70.07 % 0 % 0 %
common.calendar.number_days.180d 2.01 $ 1.08 $ 2.65 $ 15.92 % 0 % 0 %
common.calendar.number_days.1y 3.37 $ 1.08 $ 3.83 $ -30.86 % 0 % 0 %
common.calendar.number_days.3y 7.87 $ 0.169 $ 6.96 $ -70.39 % 0 % 0 %
common.calendar.number_days.5y 9.85 $ 0.169 $ 12.91 $ -76.35 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.169 $ 12.91 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 2.2 $ 1.08 $ 2.65 $ 5.91 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Robert Joseph Hariri M.D., Ph.D. Founder, CEO & Chairman 1.24M 1959 (66 années)
Mr. David C. Beers C.F.A. Chief Financial Officer 455.02k 1970 (55 années)
Mr. John R. Haines Senior EVP, Global Manager & Chief Administrative Officer 503.56k 1957 (68 années)
Ramji Krishnan Chief Technology Officer N/A
Carlos Ramirez SVP of Investor Relations N/A
Mr. Kyle Harold Fletcher Esq. Executive VP, General Counsel & Chief Compliance Officer N/A 1985 (40 années)
Dr. Stephen A. Brigido D.P.M. President of Degenerative Diseases N/A 1976 (49 années)
Sharmila Koppisetti M.D. Senior Vice President of Clinical Dev. Immunology & Drug Safety N/A
Mr. Tim Wilk Senior Vice President of Technical Operations N/A
Mr. David Jakob Lemus CPA, M.S., MBA Treasurer 1962 (63 année)

Informations sur l'entreprise

Adresse: United States, Florham Park. NJ, 170 Park Avenue - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.celularity.com